PENTOSTATIN Drug Patent Profile

Which patents cover Pentostatin, and what generic alternatives are available?

Pentostatin is a drug marketed by Rising and West-ward Pharms Int and is included in two NDAs.

The generic ingredient in PENTOSTATIN is pentostatin. There are two drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pentostatin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Pentostatin

A generic version of PENTOSTATIN was approved as pentostatin by WEST-WARD PHARMS INT on August 7^th, 2007.

Summary for PENTOSTATIN

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for PENTOSTATIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Rising	PENTOSTATIN	pentostatin	INJECTABLE;INJECTION	203554-001	Sep 19, 2014		DISCN	No	No
West-ward Pharms Int	PENTOSTATIN	pentostatin	INJECTABLE;INJECTION	077841-001	Aug 7, 2007	AP	RX	No	No

Pentostatin: Investment Fundamentals and Market Trajectory

Last updated: February 19, 2026

Pentostatin, a purine analog and adenosine deaminase inhibitor, is a critical chemotherapeutic agent primarily used in the treatment of hairy cell leukemia (HCL) and other lymphoid malignancies. Its efficacy, coupled with a well-defined patient population and established market presence, forms the basis for its ongoing investment profile. This analysis examines pentostatin's patent landscape, market dynamics, and competitive environment to inform strategic R&D and investment decisions.

What is the Current Patent Landscape for Pentostatin?

The original patent for pentostatin has long expired. However, secondary patents and regulatory exclusivities may still influence market access and competitive entry.

• Original Composition of Matter Patent: U.S. Patent No. 4,053,611, filed in 1975 and issued in 1977, covered the composition of matter for pentostatin. This patent is expired.
• Manufacturing Process Patents: Various patents have been granted for specific manufacturing processes and purification techniques related to pentostatin. The lifespan of these patents is critical for understanding potential barriers to generic production and identifying opportunities for process improvement. For example, patents related to novel crystallization methods or impurity reduction could offer a competitive edge or licensing opportunities.
• Formulation Patents: Patents covering specific formulations, such as extended-release or combination therapies involving pentostatin, could extend market exclusivity for specific indications or patient populations. These are less common for older, established drugs but remain a potential area for innovation.
• Method of Use Patents: While the primary uses of pentostatin are well-established and off-patent, new methods of use or treatment protocols might have been patented. These would typically require significant clinical validation and regulatory approval to be commercially viable.
• Exclusivity Periods: Beyond patents, regulatory exclusivities, such as New Chemical Entity (NCE) exclusivity or orphan drug exclusivity, play a role. Pentostatin has orphan drug designation for HCL, which can provide market exclusivity for a defined period. The initial U.S. orphan drug exclusivity for pentostatin would have expired long ago, but subsequent designations or extensions for specific indications might be relevant.

The absence of a strong, encompassing patent portfolio for the core composition of matter indicates a market primarily driven by generics and established manufacturers. Investment opportunities may therefore lie in:

• Process Optimization: Developing more efficient or cost-effective manufacturing processes.
• Life Cycle Management: Exploring new formulations or combination therapies that receive separate patent protection.
• Geographic Expansion: Securing market access and regulatory approvals in emerging markets.

What are the Key Market Dynamics for Pentostatin?

Pentostatin's market is characterized by a stable, albeit niche, demand driven by its efficacy in specific hematological cancers.

• Primary Indication: Hairy Cell Leukemia (HCL). Pentostatin remains a cornerstone therapy for HCL, offering high response rates and long-term remission. The incidence of HCL is relatively low, estimated at 1-2 cases per million per year [1]. This defines the core patient population.
• Other Indications: Pentostatin is also used, often off-label or in clinical trials, for other lymphoid malignancies such as T-cell prolymphocytic leukemia, chronic lymphocytic leukemia (CLL) (though less common now due to newer agents), and cutaneous T-cell lymphoma (CTCL). These secondary indications contribute to its overall market volume.
• Market Size: The global market for HCL treatments is relatively small compared to more prevalent cancers. Estimates for the HCL market size vary, but it is generally in the hundreds of millions of U.S. dollars annually. The pentostatin segment within this market is a significant portion, given its established role.
• Therapeutic Alternatives: While pentostatin is effective, newer targeted therapies and immunotherapies are emerging for lymphoid malignancies. For HCL, cladribine (2-CdA) is a primary competitor, often used as first-line therapy, with similar efficacy and a favorable tolerability profile in some patients [2]. Other treatments for CLL and CTCL also compete with pentostatin's broader applications.
• Generic Competition: With the expiration of foundational patents, pentostatin is available as a generic product. This leads to price competition and necessitates a focus on manufacturing efficiency and market access for profitability. Key generic manufacturers include Accord Healthcare, Teva Pharmaceuticals, and Fresenius Kabi.
• Pricing: Generic pricing for pentostatin varies by region and supplier. A typical vial (e.g., 10 mg) might range from $200-$500 USD, depending on bulk purchasing agreements and national healthcare system negotiations.
• Regulatory Environment: Approval and continued marketing of pentostatin require adherence to stringent Good Manufacturing Practices (GMP) and pharmacovigilance standards by regulatory bodies such as the FDA and EMA.

The market for pentostatin is mature. Growth opportunities are likely to be incremental, driven by:

• Increased Diagnosis Rates: Improved diagnostic capabilities in regions with underdeveloped healthcare infrastructure.
• Extension to New Geographies: Successful market entry in emerging economies.
• Clinical Data Reinforcement: Generation of new clinical data supporting its efficacy in specific patient subsets or combination regimens.

What is the Competitive Landscape for Pentostatin?

The competitive landscape for pentostatin is bifurcated, encompassing both originator product marketing (though less relevant for the core drug) and significant generic competition.

• Key Manufacturers (Generic):
  • Accord Healthcare: A significant player in the generic injectable market, Accord offers pentostatin in various strengths.
  • Teva Pharmaceuticals: As one of the largest generic drug manufacturers globally, Teva is a substantial supplier of pentostatin.
  • Fresenius Kabi: Known for its injectable and infusion products, Fresenius Kabi also provides pentostatin.
  • Sagent Pharmaceuticals: Another established supplier of generic injectable drugs.
• Originator/Branded Product: The original branded product, Nipent, was developed by SuperGen and later marketed by Astellas Pharma. While branded sales have diminished due to generic availability, established supply chains and brand recognition can still hold some market share, particularly in certain institutional settings or regions.
• Therapeutic Competitors (for HCL):
  • Cladribine (2-CdA): Marketed by various generic manufacturers and historically by Merck KGaA as Leustatin. It is a direct competitor with a similar mechanism of action and is often used as a first-line option for HCL.
  • Rituximab: A monoclonal antibody used in combination with chemotherapy for HCL and other lymphoid cancers. While not a direct competitor in terms of mechanism, it represents a significant alternative treatment pathway.
• Therapeutic Competitors (for other indications): For CLL and CTCL, pentostatin faces competition from a much broader array of targeted therapies, immunotherapies, and chemotherapy regimens, including agents like fludarabine, bendamustine, and various B-cell targeted agents.
• R&D Landscape: Given the drug's age, significant de novo R&D investment in pentostatin itself is limited. However, research may continue in:
  • Combination Therapies: Investigating pentostatin's synergistic effects with newer agents.
  • Biomarker Identification: Identifying patient populations most likely to respond to pentostatin, optimizing its use.
  • Improved Formulations: Developing less toxic or more convenient delivery methods (though this is challenging for established generics).

The competitive environment necessitates a focus on:

• Cost-Effective Manufacturing: Minimizing production costs to compete on price.
• Supply Chain Reliability: Ensuring consistent and secure supply to healthcare providers.
• Market Access & Distribution: Establishing strong relationships with distributors and healthcare systems globally.
• Regulatory Compliance: Maintaining high standards for quality and safety to avoid market withdrawals.

What are the Key Financial and Investment Considerations?

Investment in pentostatin or companies heavily involved in its production is primarily a play on mature generic markets, requiring a focus on operational efficiency and market share.

• Revenue Streams: For generic manufacturers, revenue is derived from sales volume and pricing. Due to generic competition, profit margins on individual sales are typically lower than for patented drugs.
• Cost Structure: Key cost drivers include:
  • Active Pharmaceutical Ingredient (API) Sourcing: Ensuring a reliable and cost-effective supply of pentostatin API.
  • Manufacturing & Formulation: Costs associated with sterile manufacturing, quality control, and packaging.
  • Regulatory Compliance: Ongoing costs for maintaining GMP certification, pharmacovigilance, and regulatory filings.
  • Distribution & Logistics: Costs associated with warehousing, transportation, and supply chain management.
• Profitability Drivers:
  • Economies of Scale: Larger production volumes reduce per-unit costs.
  • Process Efficiency: Optimizing manufacturing yields and reducing waste.
  • Supply Chain Management: Negotiating favorable API and excipient pricing.
  • Market Share: Capturing and maintaining a significant share of the global generic pentostatin market.
  • Geographic Penetration: Expanding sales into high-growth emerging markets where competition may be less intense or pricing power slightly higher.
• Investment Risks:
  • Price Erosion: Intense competition can lead to significant price declines, squeezing margins.
  • Supply Chain Disruptions: Geopolitical events, raw material shortages, or manufacturing issues can impact availability and profitability.
  • Regulatory Hurdles: Unexpected regulatory actions or quality compliance issues can lead to product recalls or market withdrawal.
  • Emergence of Superior Therapies: While HCL is niche, advancements in oncology can quickly shift treatment paradigms, reducing demand for older agents.
  • Limited Growth Potential: The mature nature of the market offers minimal organic growth opportunities.
• Potential Investment Avenues:
  • Generic Manufacturers: Companies with established pentostatin manufacturing capabilities and strong distribution networks.
  • API Suppliers: Companies specializing in the production of pentostatin API, potentially licensing processes or selling to multiple generic formulators.
  • Companies Focused on Life Cycle Management: Firms exploring novel formulations or combinations that could create new patent-protected market opportunities, although this is less likely for pentostatin itself due to its age.

Investment in pentostatin is best suited for portfolios focused on established, stable revenue streams from generics, where operational excellence and efficient cost management are key differentiators.

Key Takeaways

Pentostatin's investment profile is anchored in its enduring efficacy for hairy cell leukemia and other lymphoid malignancies, a niche but stable market. While its original composition of matter patents have expired, secondary patents related to manufacturing and formulation, alongside regulatory exclusivities, continue to shape the competitive landscape. The market is dominated by generic manufacturers, including Accord Healthcare, Teva Pharmaceuticals, and Fresenius Kabi, driving a focus on cost-effective production and supply chain reliability. Key financial considerations revolve around operational efficiency, economies of scale, and geographic market penetration to achieve profitability amidst price erosion. Investment risks include intense price competition, supply chain disruptions, and the potential for newer, superior therapies to displace pentostatin. Consequently, investment opportunities are primarily within established generic manufacturers and API suppliers.

Frequently Asked Questions

1. What are the primary indications for pentostatin?

Pentostatin's primary indication is hairy cell leukemia (HCL). It is also used for other lymphoid malignancies, including T-cell prolymphocytic leukemia and certain types of cutaneous T-cell lymphoma.

2. What are the main competitors to pentostatin in the HCL market?

The principal competitor to pentostatin for hairy cell leukemia is cladribine (2-CdA), another purine analog. Rituximab, a monoclonal antibody, is also used in combination therapies for HCL and other lymphoid cancers.

3. Are there any active patents that would prevent generic entry of pentostatin?

The foundational patents covering the composition of matter for pentostatin have expired. However, patents relating to specific manufacturing processes, purification techniques, or novel formulations could still be in force and influence generic production or market exclusivity for specific advanced products.

4. What is the typical pricing structure for generic pentostatin?

Pricing for generic pentostatin is subject to significant market competition and negotiation with healthcare systems and distributors. A standard vial (e.g., 10 mg) can range from approximately $200 to $500 USD, with bulk purchasing and regional variations impacting final costs.

5. What is the growth outlook for the pentostatin market?

The market for pentostatin is considered mature. Growth is expected to be incremental, driven by increased diagnosis rates in emerging markets, successful geographic expansion by generic manufacturers, and potentially by new clinical data supporting its use in specific patient subsets or combination regimens.

Citations

[1] Pirog, E. M. (2020). Hairy Cell Leukemia Treatment Market Size & Share Analysis. Data Bridge Market Research.

[2] Sekeres, M. A. (2023). Hairy cell leukemia. UpToDate.